1. Home
  2. FUND vs CABA Comparison

FUND vs CABA Comparison

Compare FUND & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUND

Sprott Focus Trust Inc.

N/A

Current Price

$9.82

Market Cap

289.8M

Sector

Finance

ML Signal

N/A

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

N/A

Current Price

$1.48

Market Cap

339.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FUND
CABA
Founded
1988
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
289.8M
339.1M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
FUND
CABA
Price
$9.82
$1.48
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $11.75
AVG Volume (30 Days)
15.3K
★ 4.9M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 6.64%
N/A
EPS Growth
N/A
★ 10.26
EPS
★ 0.93
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.59
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.97
$1.18
52 Week High
$10.99
$4.23

Technical Indicators

Market Signals
Indicator
FUND
CABA
Relative Strength Index (RSI) 50.32 41.97
Support Level $9.87 N/A
Resistance Level $10.08 $1.63
Average True Range (ATR) 0.17 0.14
MACD 0.02 0.04
Stochastic Oscillator 56.36 63.33

Price Performance

Historical Comparison
FUND
CABA

About FUND Sprott Focus Trust Inc.

Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: